Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypothyroidism after Hemithyroidectomy: A Randomised Controlled Trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524175-23-00

Enrollment

Registered

2026-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothyroidism, Incident Kidney Dysfunction, Chronic Kidney Disease

Brief summary

Change eGFR from baseline to 3 months postoperatively, measured in mL/min/1.73m² using standard laboratory methods.

Detailed description

Serum levels of TSH, T4, and T3 at 3 months postoperatively., ThyPRO-39 composite score changes from baseline to 3 and 6 months postoperatively., Change in body weight (kg) and BMI (kg/m²) from baseline to 3 months and 6 months., In control group participants who initiate THRT at 3 months due to elevated TSH (>1.5 mIU/L), follow-up changes in eGFR and HRQoL at 6 months.

Interventions

DRUGLEVOTHYROXINE SODIUM

DRUGLEVOTHYROXINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change eGFR from baseline to 3 months postoperatively, measured in mL/min/1.73m² using standard laboratory methods.	—

Secondary

Measure	Time frame
Serum levels of TSH, T4, and T3 at 3 months postoperatively., ThyPRO-39 composite score changes from baseline to 3 and 6 months postoperatively., Change in body weight (kg) and BMI (kg/m²) from baseline to 3 months and 6 months., In control group participants who initiate THRT at 3 months due to elevated TSH (>1.5 mIU/L), follow-up changes in eGFR and HRQoL at 6 months.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 4, 2026